MarketCap
Facebook
X
Telegram
Country |
 France |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
1.22 B |
Market Cap[1] |
$ 57.9 B |
EBITDA (LTM) |
$ 6.34 B |
P/E (LTM) |
6.929688 |
P/S (LTM) |
- |
EPS (LTM) |
6.4 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
CNS Pharmaceuticals
CNSP
|
$ 4.21 | -7.47 % | $ 1.87 M | Nasdaq Capital Market |  USA |
 |
Spero Therapeutics
SPRO
|
$ 1.07 | 2.88 % | $ 59.9 M | Nasdaq Global Select Market | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 10.79 | 7.85 % | $ 507 M | Nasdaq Capital Market | USA |
 |
Sarepta Therapeutics
SRPT
|
$ 18.97 | 2.32 % | $ 1.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 21.07 | 1.52 % | $ 33.3 B | NYSE |  Japan |
 |
Tarsus Pharmaceuticals
TARS
|
$ 69.01 | -5.0 % | $ 2.88 B | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Bio-Techne Corporation
TECH
|
$ 72.8 | 0.19 % | $ 11.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 41.97 | 0.14 % | $ 48.1 B | NYSE |  Israel |
 |
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | USA |
 |
Precision BioSciences
DTIL
|
$ 8.01 | 14.92 % | $ 103 M | Nasdaq Global Select Market | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 5.12 | -1.45 % | $ 43.6 M | Nasdaq Global Select Market | USA |
 |
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | USA |
 |
Taysha Gene Therapies
TSHA
|
$ 4.34 | 5.99 % | $ 1.39 B | Nasdaq Global Select Market | USA |
 |
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.56 | -2.77 % | $ 6.2 M | Nasdaq Capital Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | USA |
 |
Annovis Bio
ANVS
|
$ 1.2 | 9.63 % | $ 24.7 M | NYSE American | USA |
 |
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | USA |
 |
Vericel Corporation
VCEL
|
$ 45.83 | 11.54 % | $ 2.31 B | Nasdaq Global Select Market,SPB | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Veracyte
VCYT
|
$ 52.31 | 4.02 % | $ 4.11 B | Nasdaq Global Market,SPB | USA |
 |
Exelixis
EXEL
|
$ 72.73 | 0.58 % | $ 19.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | USA |
 |
Vir Biotechnology
VIR
|
$ 11.67 | 4.01 % | $ 1.62 B | Nasdaq Global Select Market,SPB | USA |
 |
Viking Therapeutics
VKTX
|
$ 27.96 | 7.17 % | $ 3.15 B | Nasdaq Capital Market | USA |
 |
Vanda Pharmaceuticals
VNDA
|
$ 3.87 | 3.07 % | $ 228 M | Nasdaq Global Select Market,SPB | USA |
 |
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.45 | 4.86 % | $ 36.8 M | Nasdaq Global Market | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 549.04 | 3.44 % | $ 140 B | Nasdaq Global Select Market,SPB | USA |
 |
vTv Therapeutics
VTVT
|
$ 23.99 | 1.87 % | $ 94.9 M | Nasdaq Global Select Market | USA |
 |
Voyager Therapeutics
VYGR
|
$ 1.88 | 2.46 % | $ 110 M | Nasdaq Global Select Market | USA |
 |
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | USA |
 |
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | USA |
 |
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | USA |
 |
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | USA |
 |
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | USA |
 |
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market |  Canada |
 |
Xenetic Biosciences
XBIO
|
$ 2.03 | -2.64 % | $ 3.45 M | Nasdaq Capital Market | USA |
 |
Xeris Pharmaceuticals
XERS
|
$ 10.48 | 1.21 % | $ 1.68 B | Nasdaq Global Select Market | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 10.35 | -3.27 % | $ 296 M | Nasdaq Capital Market | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 3.23 | 1.74 % | $ 137 M | Nasdaq Capital Market | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.01 | -5.61 % | $ 11.4 M | Nasdaq Capital Market | USA |
 |
Atea Pharmaceuticals
AVIR
|
$ 4.46 | 6.83 % | $ 363 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.